EPICS Therapeutics is a cutting-edge drug discovery and development company that focuses on inventing and developing small molecule drugs to target RNA epigenetic mechanisms involved in cancer development. With a strong dedication to tackling serious unmet medical needs in the field of oncology, EPICS is driven by a mission to deliver novel clinical agents and meet high value-added endpoints. As a brand, EPICS balances risk and reward in determining partnerships for their programs, constantly striving for excellence in their endeavors.

They have an impressive timeline, incorporating as a spin-off from the University of Brussels in March 2018 and completing a seed-fund round amounting to €7. 2M in April of that year. In December 2018, EPICS acquired Ogeda's former assets, expanding their capabilities.

Led by a talented management team and board of directors, EPICS Therapeutics boasts a lineup of experts who are at the forefront of their respective fields. They have a diverse range of expertise in areas such as drug discovery, scientific research, medical direction, intellectual property, and more. Located in Gosselies, Belgium, EPICS can be reached via telephone at +32 71 348 500 or by email at info@epicstherapeutics.

com. They also offer Euroscreen Fast, a business unit that provides integrated services for GPCR R&D projects. Discover more about EPICS Therapeutics on their website, where you can find information about their science, news, partnerships, publications, events, and job opportunities